{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:21:20Z","timestamp":1793924480344,"version":"4.8.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.bulcan.2022.10.001","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T08:22:10Z","timestamp":1667809330000},"page":"9-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nouvelles AMM\u00a0: le tebentafusp dans le m\u00e9lanome uv\u00e9al m\u00e9tastatique HLA A*02:01\u00a0positif"],"prefix":"10.1016","volume":"110","author":[{"given":"Antoine","family":"Gaillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Matet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bulcan.2022.10.001_bib0035","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.bulcan.2018.07.011","article-title":"Prise en charge des m\u00e9lanomes oculaires, le minimum pour les oncologues","volume":"105","author":"Mathis","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.bulcan.2022.10.001_bib0040","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A phase III, multicenter, randomized trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.10.001_bib0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2022.06.033","article-title":"MBD4\u00a0deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients","volume":"173","author":"Saint-Ghislain","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2022.10.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bulcan.2022.10.001_bib0055","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2022.10.001_bib0030","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:37:44Z","timestamp":1757792264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122003940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0007455122003940"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.10.001","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nouvelles AMM\u00a0: le tebentafusp dans le m\u00e9lanome uv\u00e9al m\u00e9tastatique HLA A*02:01\u00a0positif","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}